Clinical pharmacology of isophosphamide.
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001830:Body Surface Area; D002250:Carbon Radioisotopes; D002854:Chromatography, Paper; D002855:Chromatography, Thin Layer; D002986:Clinical Trials as Topic; D003498:Cyclic P-Oxides / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D005021:Ethylamines / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010078:Oxazines / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013997:Time Factors; D001745:Urinary Bladder Diseases / Q000139:chemically induced
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D003498:Cyclic P-Oxides; D005021:Ethylamines; D010078:Oxazines